Drug intelligence / Profile preview

PH039

Development stage: Preclinical
Lead developer: Suzhou Puhe Biopharma
Modality: Small Molecules

Overview

PH039 is a preclinical-stage small molecule pan-EGFR inhibitor being developed by Suzhou Puzheng Pharma (also known as Puhe Biopharma) for the treatment of non-small cell lung cancer (NSCLC). As a pan-EGFR inhibitor, it is designed to target multiple mutations or forms of the epidermal growth factor receptor (EGFR) kinase, potentially offering a broader therapeutic window or overcoming resistance mechanisms associated with more selective EGFR inhibitors. The drug is currently in the preclinical or Investigational New Drug (IND) enabling phase of development.

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on PH039.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PH039.

Explore the full profile